Developer docs
API playgroundTry for free, no card

Search company profiles

Aiolos Bio

Full company profile

uuid0000pfl

Namestring
Aiolos Bio
Legal namestring
Aiolos Bio
Websiteurl
aiolosbio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Aiolos Bio is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in San Francisco that develops monoclonal antibody therapies for respiratory and immunology indications. The company's lead asset, AIO-001, is an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody licensed on an exclusive basis from Jiangsu Hengrui Pharmaceuticals for all territories outside greater China. AIO-001's differentiated pharmacokinetic profile supports a twice-yearly dosing schedule, addressing the chronic adherence burden associated with existing biologic therapies for severe asthma.

AIO-001 is being developed as a multi-indication asset. The lead program targets moderate-to-severe asthma and is in Phase 2 development, while exploratory work is underway in chronic obstructive pulmonary disease (COPD) and chronic spontaneous urticaria (CSU). The molecule has already been administered to more than 100 patients in prior Hengrui-conducted clinical work, providing a meaningful human safety and pharmacokinetic dataset for the US/EU development pathway. The asset was in-licensed alongside a $245 million Series A financing closed in October 2023 — one of the largest biotech Series A rounds of that year — from a syndicate comprising Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners, RA Capital Management, and Sofinnova Investments.

Aiolos Bio is pre-revenue and monetizes through future product commercialization post-regulatory approval rather than current sales. The company's leadership includes co-founder and CEO Khurem Farooq and co-founder Ashley Taylor. Operating model is a capital-intensive clinical development organization, with current spending focused on Phase 2 execution in asthma, exploratory work in COPD and CSU, and buildout of the US/EU development infrastructure required for a global regulatory filing.

Short descriptiontext

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, a twice-yearly anti-TSLP monoclonal antibody in-licensed from Hengrui Pharmaceuticals, for severe asthma (Phase 2) plus exploratory COPD and CSU programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
monoclonal antibody therapy, respiratory disease treatment, anti-TSLP antibody, inflammatory disease therapy, clinical-stage biopharmaceuticals
Industry2 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals (Respiratory and Inflammatory Therapeutics)
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody targeting severe asthma, COPD, and chronic spontaneous urticaria (CSU). The asset was in-licensed from Jiangsu Hengrui Pharmaceuticals with exclusive development rights outside of greater China and has been tested in over 100 patients. AIO-001 is designed for twice-yearly dosing, and the company plans to advance it through Phase 2 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Tested in over 100 patients with promising results supporting continued clinical development
Product overview1 text field

Aiolos Bio is a biopharmaceutical company focused on developing AIO-001, an anti-TSLP monoclonal antibody for respiratory and inflammatory conditions. The company launched in October 2023 with $245 million Series A funding, one of the largest biotech Series A rounds that year, to advance AIO-001 into Phase 2 clinical trials for severe asthma and explore its potential for COPD and CSU.

Product and service1 record
1AIO-001 (Anti-TSLP Antibody)
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Jiangsu Hengrui Pharmaceuticals
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-10-24
Description

Aiolos Bio acquired exclusive development rights for AIO-001 (anti-TSLP antibody) outside of greater China from Jiangsu Hengrui Pharmaceuticals. This licensing arrangement enabled Aiolos Bio to launch with $245 million Series A funding to advance the drug candidate through Phase 2 clinical trials for severe asthma and explore additional indications including COPD and chronic spontaneous urticaria.

vcaonline.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Regeneron co-developed Dupixent with Sanofi, the leading biologic in severe asthma and CSU. The drug competes head-to-head with the indications Aiolos Bio is pursuing.

TypeDirect peer
Description

AstraZeneca co-developed and commercializes Tezspire (tezepelumab) with Amgen—an anti-TSLP antibody already approved for severe asthma. It is the most direct therapeutic and mechanistic competitor to Aiolos Bio's AIO-001.

TypeDirect peer
Description

Amgen originally developed tezepelumab (now marketed as Tezspire with AstraZeneca), the only approved anti-TSLP antibody for severe asthma. It is the closest mechanistic competitor to AIO-001.

TypeBroad incumbent
Description

Sanofi co-markets Dupixent (dupilumab) with Regeneron, approved in both severe asthma and chronic spontaneous urticaria—directly overlapping Aiolos Bio's lead and exploratory indications and setting the efficacy bar AIO-001 must beat.

TypeBroad incumbent
Description

GSK markets Nucala (mepolizumab) and other respiratory biologics, including programs targeting TSLP-related inflammation. It is a broad incumbent in the respiratory/inflammation therapeutic area where Aiolos Bio competes.

TypeBroad incumbent
Description

Roche co-markets Xolair (omalizumab) with Novartis, approved for chronic spontaneous urticaria—one of Aiolos Bio's exploratory indications. It is a direct competitor in the CSU indication.

TypeBroad incumbent
Description

Novartis co-markets Xolair with Roche (relevant to CSU) and has a broader respiratory portfolio, making it a broad incumbent whose commercial footprint competes with AIO-001's potential launch.

TypeBroad incumbent
Description

Teva maintains a respiratory franchise (including severe asthma and COPD products) and represents a broad incumbent competitor whose commercial reach could affect AIO-001's uptake trajectory.

TypeEmerging player
Description

Theravance Biopharma is a clinical-stage company focused on respiratory diseases, sharing Aiolos Bio's therapeutic area focus on respiratory inflammation and offering a comparable development-stage peer for capital and pipeline benchmarking.

TypeEmerging player
Description

Connect Biopharma is a clinical-stage immunology company developing therapies for inflammatory diseases, providing a useful emerging-stage peer for comparison of capital efficiency and clinical execution in immunology-focused biotechs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aiolos Bio

Biopharmaceuticals (Respiratory and Inflammatory Therapeutics)aiolosbio.com

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, a twice-yearly anti-TSLP monoclonal antibody in-licensed from Hengrui Pharmaceuticals, for severe asthma (Phase 2) plus exploratory COPD and CSU programs.

What Aiolos Bio does

Aiolos Bio is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in San Francisco that develops monoclonal antibody therapies for respiratory and immunology indications. The company's lead asset, AIO-001, is an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody licensed on an exclusive basis from Jiangsu Hengrui Pharmaceuticals for all territories outside greater China. AIO-001's differentiated pharmacokinetic profile supports a twice-yearly dosing schedule, addressing the chronic adherence burden associated with existing biologic therapies for severe asthma.

AIO-001 is being developed as a multi-indication asset. The lead program targets moderate-to-severe asthma and is in Phase 2 development, while exploratory work is underway in chronic obstructive pulmonary disease (COPD) and chronic spontaneous urticaria (CSU). The molecule has already been administered to more than 100 patients in prior Hengrui-conducted clinical work, providing a meaningful human safety and pharmacokinetic dataset for the US/EU development pathway. The asset was in-licensed alongside a $245 million Series A financing closed in October 2023 — one of the largest biotech Series A rounds of that year — from a syndicate comprising Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners, RA Capital Management, and Sofinnova Investments.

Aiolos Bio is pre-revenue and monetizes through future product commercialization post-regulatory approval rather than current sales. The company's leadership includes co-founder and CEO Khurem Farooq and co-founder Ashley Taylor. Operating model is a capital-intensive clinical development organization, with current spending focused on Phase 2 execution in asthma, exploratory work in COPD and CSU, and buildout of the US/EU development infrastructure required for a global regulatory filing.

Aiolos Bio firmographics

Firmographics
Name
Aiolos Bio
Legal name
Aiolos Bio
Website
https://aiolosbio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, a twice-yearly anti-TSLP monoclonal antibody in-licensed from Hengrui Pharmaceuticals, for severe asthma (Phase 2) plus exploratory COPD and CSU programs.
Ownership category
akta.pro rank

Aiolos Bio industry classification

Industry
Product category
Biopharmaceuticals (Respiratory and Inflammatory Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Monoclonal antibody therapy
  • Respiratory disease treatment
  • Anti-TSLP antibody
  • Inflammatory disease therapy
  • Clinical-stage biopharmaceuticals

Where Aiolos Bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Aiolos Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Aiolos Bio product offering

Product offering

Core offering

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody targeting severe asthma, COPD, and chronic spontaneous urticaria (CSU). The asset was in-licensed from Jiangsu Hengrui Pharmaceuticals with exclusive development rights outside of greater China and has been tested in over 100 patients. AIO-001 is designed for twice-yearly dosing, and the company plans to advance it through Phase 2 clinical trials.

Product overview

Aiolos Bio is a biopharmaceutical company focused on developing AIO-001, an anti-TSLP monoclonal antibody for respiratory and inflammatory conditions. The company launched in October 2023 with $245 million Series A funding, one of the largest biotech Series A rounds that year, to advance AIO-001 into Phase 2 clinical trials for severe asthma and explore its potential for COPD and CSU.

Differentiator

Problem solved

Functional benefit

Products and services

  • AIO-001 (Anti-TSLP Antibody)

Quantifiable outcome

  • Tested in over 100 patients with promising results supporting continued clinical development

Companies that use Aiolos Bio

Customer profile

Segments3 records

Ideal customer profiles2 records

Aiolos Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Aiolos Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Jiangsu Hengrui PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 24 October 2023Aiolos Bio acquired exclusive development rights for AIO-001 (anti-TSLP antibody) outside of greater China from Jiangsu Hengrui Pharmaceuticals. This licensing arrangement enabled Aiolos Bio to launch with $245 million Series A funding to advance the drug candidate through Phase 2 clinical trials for severe asthma and explore additional indications including COPD and chronic spontaneous urticaria.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Aiolos Bio competitors and assessment

Company assessment

Broad incumbents

  • Regeneron: Regeneron co-developed Dupixent with Sanofi, the leading biologic in severe asthma and CSU. The drug competes head-to-head with the indications Aiolos Bio is pursuing.
  • Sanofi: Sanofi co-markets Dupixent (dupilumab) with Regeneron, approved in both severe asthma and chronic spontaneous urticaria—directly overlapping Aiolos Bio's lead and exploratory indications and setting the efficacy bar AIO-001 must beat.
  • GSK: GSK markets Nucala (mepolizumab) and other respiratory biologics, including programs targeting TSLP-related inflammation. It is a broad incumbent in the respiratory/inflammation therapeutic area where Aiolos Bio competes.
  • Roche: Roche co-markets Xolair (omalizumab) with Novartis, approved for chronic spontaneous urticaria—one of Aiolos Bio's exploratory indications. It is a direct competitor in the CSU indication.
  • Novartis: Novartis co-markets Xolair with Roche (relevant to CSU) and has a broader respiratory portfolio, making it a broad incumbent whose commercial footprint competes with AIO-001's potential launch.
  • Teva Pharmaceutical Industries: Teva maintains a respiratory franchise (including severe asthma and COPD products) and represents a broad incumbent competitor whose commercial reach could affect AIO-001's uptake trajectory.

Direct peers

  • AstraZeneca: AstraZeneca co-developed and commercializes Tezspire (tezepelumab) with Amgen—an anti-TSLP antibody already approved for severe asthma. It is the most direct therapeutic and mechanistic competitor to Aiolos Bio's AIO-001.
  • Amgen: Amgen originally developed tezepelumab (now marketed as Tezspire with AstraZeneca), the only approved anti-TSLP antibody for severe asthma. It is the closest mechanistic competitor to AIO-001.

Emerging players

  • Theravance Biopharma: Theravance Biopharma is a clinical-stage company focused on respiratory diseases, sharing Aiolos Bio's therapeutic area focus on respiratory inflammation and offering a comparable development-stage peer for capital and pipeline benchmarking.
  • Connect Biopharma: Connect Biopharma is a clinical-stage immunology company developing therapies for inflammatory diseases, providing a useful emerging-stage peer for comparison of capital efficiency and clinical execution in immunology-focused biotechs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Aiolos Bio social profiles

Digital presence

Aiolos Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aiolos Bio leadership team

Management profile

Number of profiles

Profiles2 records

Aiolos Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aiolos Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aiolos Bio

What does Aiolos Bio do?

Aiolos Bio is a clinical-stage biopharmaceutical company developing AIO-001, an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody targeting severe asthma, COPD, and chronic spontaneous urticaria (CSU). The asset was in-licensed from Jiangsu Hengrui Pharmaceuticals with exclusive development rights outside of greater China and has been tested in over 100 patients. AIO-001 is designed for twice-yearly dosing, and the company plans to advance it through Phase 2 clinical trials.

Is Aiolos Bio a public or private company?

Aiolos Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aiolos Bio founded?

Aiolos Bio was founded in 2023. It employs 1 to 10 people.

Where is Aiolos Bio based?

Aiolos Bio is headquartered in San Francisco, United States, in the North America region.

Who are Aiolos Bio's main competitors?

Broad incumbents on record are Regeneron, Sanofi, GSK, Roche, Novartis and Teva Pharmaceutical Industries. Direct peers are AstraZeneca and Amgen. Emerging players are Theravance Biopharma and Connect Biopharma.

Does Aiolos Bio have an API?

No public API is recorded for Aiolos Bio.

What industry is Aiolos Bio in?

Aiolos Bio's product category is Biopharmaceuticals (Respiratory and Inflammatory Therapeutics). Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Leaders and Emerging Competitors in the Anti-Asthmatics and COPD Drugs Industry: A Competitive AnalysisThe anti-asthmatics and COPD drugs market is set to grow significantly, with projections reaching $111.34 billion by 2030, driven by advancements like biologics and artificial intelligence. A notable strategic acquisition occurred in February 2024 when GSK plc acquired Aiolos Bio for $1 billion to enhance its respiratory portfolio. This acquisition highlights the increasing focus on targeted therapies for severe asthma patients.openPR.comLeading Companies Propelling Innovation and Growth in the Eosinophilic Asthma MarketThe eosinophilic asthma market is projected to reach $6.92 billion by 2030, growing at a compound annual growth rate of 16.9%, driven by advances in precision treatments, biologic drug pipelines, biomarker-based diagnostics, and the expansion of specialized respiratory clinics. In February 2024, GSK plc acquired US-based Aiolos Bio for $1 billion to strengthen its respiratory portfolio and target severe asthma patients with low T2 inflammation, representing a significant strategic move in the sector.South China Morning Post6 of the best: how China’s new biotech vanguard is banking billions from breakthroughsChina's biotech sector saw record licensing deals, including MSD's $175 million upfront plus up to $9.3 billion in milestones for seven ADC candidates from Kelun-Biotech. Eight months later, Aiolos licensed an asthma treatment from Hengrui Pharmaceuticals for an undisclosed sum.American City Business JournalsNference sues Aiolos Bio over alleged theft of asthma drugAn asthma drug biotech acquired by GSK in a deal worth up to $1.4 billion is the subject of a lawsuit. The case involves tens of millions of dollars at stake.ThenonexecutiveLatest UK M&A Statistics for Q1-24The UK Office for National Statistics released Q1 2024 M&A statistics showing 426 total transactions, down 18 from the previous quarter, with monthly activity declining sharply from 174 in January to 100 in March. Outward M&A value increased to £4.4 billion while inward M&A value fell significantly to £6.1 billion, down £4.0 billion from Q4-23's £10.1 billion. Notable acquisitions included GSK's purchase of Aiolos Bio Inc and AstraZeneca's acquisition of Gracell Biotechnologies, alongside a Bank of England report noting improving investment sentiment as inflation falls and confidence that interest rates have peaked.NaturePrioritizing partnerships to get ahead of diseaseGSK is prioritizing partnerships to get ahead of disease, focusing on infectious diseases, HIV, respiratory, immunology, and oncology. The company has over 100 active alliances and recently acquired Bellus Health and Aiolos Bio, plus licensed a hepatitis B candidate. Its business development team aims to be a partner of choice by combining expertise, technology, and scale.ReutersGSK completes acquisition of Aiolos Bio for up to $1.4 blnGSK completed its acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions. The deal includes $1 billion upfront and up to $400 million in success-based milestone payments, plus tiered royalties to Jiangsu Hengrui Pharmaceuticals.MarketScreenerGsk Plc - Gsk Completes Acquisition Of Aiolos Bio…GSK plc has completed its acquisition of Aiolos Bio, enhancing its portfolio in the biopharmaceutical sector. This move is part of GSK's strategy to develop cancer therapies and address unmet treatment needs. The acquisition further positions GSK in the competitive landscape of oncology and specialized medicines.Pulse 2.0Why GSK Is Buying Aiolos Bio In A $1.4 Billion DealGSK agreed to acquire Aiolos Bio for $1 billion upfront plus up to $400 million in regulatory milestones. The deal gives GSK access to AIO-001, a long-acting anti-TSLP antibody for asthma, with potential for chronic rhinosinusitis. The acquisition is subject to regulatory clearances.BenzingaGSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio - GSK (NYSE:GSK)GSK plc has agreed to acquire Aiolos Bio Inc. for $1 billion upfront plus up to $400 million in success-based regulatory milestone payments. The acquisition provides GSK with access to AIO-001, a long-acting TSLP monoclonal antibody for asthma treatment that has demonstrated potential for twice-yearly dosing and could address the roughly 40% of severe asthma patients with low T2 inflammation. GSK intends to use this deal to expand its respiratory biologics portfolio as it faces patent expirations on its existing top-selling products by the end of the decade.